Clinical trial · Interventional
Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer
Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma
NCT00547612CI-TRIAL-00006515completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using \[18F\]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer. PURPOSE: This phase I trial is studying how well a PET scan using \[18F\]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]-labeled substance P antagonist receptor quantifier | Radiation | — | UNRESOLVED |
| high performance liquid chromatography | Other | — | UNRESOLVED |
| pharmacological study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the pancreas * Primary or metastatic disease * At least one site of measurable disease * Enrolled in an NCI protocol (either a treatment or screening protocol) such as NCI-05-C-0044 or NCI-05-C-0141 PATIENT CHARACTERISTICS: Inclusion criteria: * ECOG performance status 0-2 * WBC ≥ 1,200/mm³ * Creatinine \< 2.0 mg/dL * Negative pregnancy test * Fertile patients must agree to use effective contraception * Not pregnant or nursing Exclusion criteria: * Allergy to IV contrast * Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan PRIOR CONCURRENT THERAPY: Inclusion criteria: * More than 4 weeks since prior abdominal surgery Exclusion criteria: * Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits * Aprepitant within 72 hours of \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography
References
Publications (0)
Data not yet available
No reference posted for this study.